Kornimate/medical-research-clean huggingface dataset:
assessment of the safety and performance of a compression knee support in the prevention of injuries during sports practice

Conditions: Chronic Knee Pain; Chronic Instability of Knee Joint

Summary: decathlon has developed kneesoft100 product which is medical device designed to reduce pain and joint instability during sport practice. the objective of this multicentre study is to collect data on the related clinical complications and clinical outcomes of market-approved decathlon kneesoft100 product to demonstrate safety and performance of this device in a real-world setting.


Eligibility criteria:
inclusion criteria: * subject is aged ≥18 years old * subject has chronic pain and / or chronic knee instability * the current condition of his/her knee allows the subject to resume usual physical activity * subject has been informed and is willing to sign an informed consent form * subject is willing to comply with protocol requirements and return to the study center for all clinical evaluations and required follow-up (6 weeks) * subject is affiliated to the french social security regime exclusion criteria: * subject has conditions that may interfere with his/her ability to understand protocol requirements, participate in scheduled visits, or provide his/her informed consent * subject has worn a support (knee brace or articulated orthosis) during sports sessions during the last month * subject has any medical condition that could impact the study at investigator's discretion * subject has a known hypersensitivity or allergy to the components of the device (elastodiene, polyester) * adult subject to a legal protection measure
ykl-40 and il-6 levels in periodontal disease

Conditions: Periodontal Diseases

Summary: the primer aim of the study was to investigate saliva and gingival crevicular fluid (gcf) ykl-40 and also interleukin-6 (il-6) levels in chronic periodontitis pathogenesis.

this study consisted of two groups: 26 periodontally healthy individuals and 26 generalized chronic periodontitis patients. chronic periodontitis patients were received nonsurgical periodontal treatment. clinical measurements were recorded, saliva and gcf samples were obtained before and at first and third months after periodontal therapy. levels of ykl-40 and il-6 in saliva and gcf were analyzed by enzyme-linked immunosorbent assay.

Eligibility criteria:
inclusion criteria: group 1 inclusion criteria: * no bone and attachment loss, * gi=0, ppd≤3mm, cal≤3mm * systematically healthy patients group 2 inclusion criteria: * gi\>1, ppd≥5mm, cal≥5mm with alveolar bone loss radiographically. * systematically healthy patients exclusion criteria: * aggressive periodontitis, * patients with any other systemic diseases, * pregnant women and those in the lactation period, * patients with smoking habit and taking medication * patients received periodontal therapy in last 6 month
effect of infraorbital and infratrochlear nerve block on emergence agitation in patients undergoing septorhinoplasty

Conditions: Emergence Agitation; Pain

Summary: the purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.

emergence agitation is a postanesthetic phenomenon characterized as confusion, disorientation and violent behavior. although its etiology is not well understood, risk factors associated with the condition include pain and ent (ear, nose and throat) surgery. bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty is effective in treating postoperative pain. the investigators have designed this study to evaluate the effect of infraorbital and infratrochlear nerve block on emergence agitation in patients undergoing septorhinoplasty.

Eligibility criteria:
inclusion criteria: * septorhinoplasty * american society of anesthesiologists (asa) classification i-ii * written informed consent exclusion criteria: * asa classification greater than iii * allergy to ropivacaine * incapability to give consent * chronic pain * coagulopathy

Keywords: infraorbital nerve block infratrochlear nerve block septorhinoplasty general anesthesia postoperative analgesia
52-104 week off-therapy second extension to study cspp100a2365

Conditions: Hypertension

Summary: 52-104 week off-therapy second extension to study cspp100a2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies spp100a2365 and spp100a2365e1


Eligibility criteria:
inclusion criteria: * successful completion of study cspp100a2365e1 * patients must meet inclusion criteria set forth for trials cspp100a2365 and cspp100a2365e1 * informed consent/ patient assent exclusion criteria: •patients who did not successfully complete studies cspp100a2365 and cspp100a2365e1

Keywords: pediatric hypertension aliskiren
relationship between dopaminergic asymmetric degeneration and attentional resources in parkinson's disease.

Conditions: Parkinson Disease; Attention Disturbances

Summary: the researchers aimed to investigate the relationship between the asymmetric dopaminergic degeneration and the attentional resources in a group of patients with parkinson's disease (pd).

to bypass the impaired habitual motor-behavioural control, parkinson's disease (pd) patients may exploit the network of goal-directed mode of action. the frontostriatal connections underline this functioning, that is based on attention. since the cognitive processes are related with dopamine, the asymmetrical degeneration of the dopaminergic system affects differently the right side affected (rpd) and the left side affected (lpd) pd patients. the aim of the study was to investigate the relationship between the asymmetric dopaminergic degeneration and the attentional resources in a group of patients with pd.

Eligibility criteria:
inclusion criteria: * stage 2.5-3 according to the hoehn and yahr scale (h\&y); * stable pharmacological treatment for the last 6 weeks before the enrolment and during the hospitalization; * mini mental state examination (mmse) ≥ 24; * no evidences of dysexecutive syndrome. exclusion criteria: * any focal brain lesion detected in brain imaging studies (ct or mri) performed in the previous 12 months; * drug-induced dyskinesias; * disturbing resting and/or action tremor, corresponding to scores 2-4 in the specific items of updrs iii; * behavioral disturbances (evaluated with neuropsychiatric inventory); * visual and auditory dysfunctions according to the general clinical evaluation and medical history; * equivocal report about the side of disease onset or bilateral motor involvement.
the evolution and prognosis of moyamoya disease

Conditions: Moyamoya Disease; Revascularization; Cognitive Impairment; Functional Impairment

Summary: to investigate the evolution of imaging appearances and cognitive function of moyamoya disease (mmd) and to establish a prognosis evaluation system based on imaging biomarkers in mmd. the study may be helpful to optimize and improve the diagnosis and pretreatment assessment of mmd, and provide an important theoretical supplement to the existing guidelines for the management of mmd.

moyamoya disease (mmd) is a chronic progressive cerebrovascular disease of unknown etiology. it is characterized by chronic progressive stenosis or occlusion of bilateral internal carotid arteries and abnormal puff vessels at the base of the brain. mmd is one of the important causes of cerebrovascular accident in young and middle-aged people, which leads to about 22% of stroke. with the development of neurosurgery, revascularization can effectively reduce the risk of stroke and other cerebrovascular accidents by increasing cerebral perfusion. therefore, this project is expected to improve the diagnosis and pretreatment assessment of mmd from the traditional level of symptomatology to the level of brain cognitive function through new imaging methods and clinical approaches. the study of cognitive function changes in follow-up period or after revascularization, which is of great scientific significance for understanding the plasticity of cognitive function under different cerebral perfusion conditions, will also be conducted.

Eligibility criteria:
inclusion criteria: * patients with mmd: conventional angiography or mri examination conforms to the guidelines for diagnosis and treatment of mmd (neurol med chir (tokyo) 52, 245-266, 2012), it is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and/or the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. sign the informed consent. older than 10 and younger than 60. the education level of patients reached primary school or above (years of education ≥6). exclusion criteria: * patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. patients with vascular diseases caused by immune system disease. patients can not cooperate to complete the cognitive function test. there are other neuropsychiatric diseases that affect cognitive function (such as alzheimer's disease, parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.

Keywords: moyamoya disease revascularization cognitive impairment functional impairment
comparison of postoperative pain after gallbladder retrieval from umbilical and epigastric ports.

Conditions: Cholelithiasis

Summary: to know the association of postoperative pain after gallbladder removal from umbilical port site versus epigastric portsite, after four ports laparoscopic cholecystectomy,and the epigastric port site was found to be friendly for the patients in terms of less pain after gallbladder removal from this site after surgery.

objective: to know the association of postoperative pain after gallbladder removal from umbilical port site versus epigastric port site, after four ports laparoscopic cholecystectomy. randomized controlled trial was performed during 1-year period from january 2017 till january 2018, at a private hospital setup. both male and female patients, with age group 18 and above, in years, were considered, who were planned four ports laparoscopic cholecystectomy after typical cholelithiasis. those patients with polyps , mucocele or empyema in gallbladder or perforated gallbladder requiring emergency surgery were omitted from the study. the patients were randomly selected, 65 in which gallbladder was removed from umbilical region (group a) and 65 from epigastric region (group b) respectively. determination of postoperative pain was done on day one, at the time of release from the hospital and at follow-up time one-month post-surgery, with the help of numerical analogue scale (nas).

Eligibility criteria:
inclusion criteria: * all healthy patients without cholecystitis exclusion criteria: * acute cholecystits, mucocoele, empyema, carcinoma, peritonitis, asa 3 and 4
olanzapine for the prevention of chemotherapy induced nausea and vomiting in gynecologic oncology patients

Conditions: Gynecologic Cancer

Summary: the objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (nk1-ras) in the prevention of chemotherapy-induced nausea and vomiting (cinv) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of gynecologic malignancy * no chemotherapy in the last 12 months * scheduled to receive carboplatin (auc\>=4) and paclitaxel every three weeks * ecog performance status 0 or 1 * english speaking * willing and able to provide informed consent * laboratory values within protocol-defined parameters * no vomiting in the 24 hours prior to initiating chemotherapy * if childbearing potential exists, negative pregnancy test within 7 days prior to registration exclusion criteria: * significant cognitive compromise * history of cns disease (e.g. brain metastases, seizure disorder, dementia) * current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are ok) * concurrent radiotherapy treatment * known hypersensitivity to olanzapine * known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the last six months * history of diabetes mellitus on medication (insulin or oral glycemic agent) * alcohol abuse / chronic alcoholism * history of closed angle glaucoma * current enrollment in other clinical trials
study correlation between blood, tissue gene expression, donor derived cell free dna and histopathology in kidney transplant recipients

Conditions: Transplant;Failure,Kidney; Kidney Transplant; Kidney Rejection Transplant

Summary: this study will compare the performance of gene expression profile (gep)/ donor derived cell free deoxyribonucleic acid (dd-cfdna) tests, to the following tests: molecular microscope (mmdx) and histopathology (study of changes in tissues caused by disease) in their ability to diagnose (exactly identify) various types of injury within the transplanted kidney.

this study will evaluate the performance of the blood-based assays like gene expression panel (gep), and donor derived cell free dna (dd-cfdna) against tissue-based assays like molecular microscope (mmdx) and histopathology in their ability to more accurately detect presence of rejection among kidney transplant recipients deemed at higher than usual risk for immunologic injury i.e., rejection. furthermore, the study should shed light on the ability of the different blood- based assays to accurately discern between the different types of rejection (early cellular versus humoral) against such confirmed by histopathology and molecular microscope. the study will also shed light on the ability of these noninvasive biomarkers to be utilized as a tool of immunomodulation in addition to studying their ability to accurately confirm presence of adequately treated rejection among the recipients of kidney transplant.

Eligibility criteria:
inclusion criteria: * patients undergoing a for cause biopsy due to ongoing or suspected "injury" of the allograft. * patients will be between 3 months and 7 years post-transplant episode. * recipients of both cadaveric and living donor renal transplant are considered eligible. exclusion criteria: * no multi organ transplant recipients will be included. * pregnancy * hiv positive recipients * recipients of kidney transplant from an identical sibling * patients with active and biopsy proven bk nephropathy

Keywords: gene expression profile molecular microscope donor derived cell free dna kidney biopsy
the effect of a walking assist robot on gait function and brain activity in stroke patients and elderly adults

Conditions: Stroke; Healthy

Summary: the purpose of this study was to investigate the effects of the new wearable hip assist robot, gait enhancing and motivating system (gems) developed by samsung advanced institute of technology (samsung electronics co, ltd., korea) on gait, sit-to-stand movement and cortical activation in elderly adults and stroke patients.

in elderly adults, 1. spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system (motion analysis corporation, santa rosa, ca, usa), surface electromyography (semg) (noraxon inc., scottsdale, az, usa) and f-scan mobile system (tekscan inc., south boston, ma, usa) during 10m walking test. 2. muscle activation and foot pressure distribution are measured by surface electromyography (semg) and f-scan mobile system during five times sit-to-stand test. 3. muscle activation and foot pressure distribution are measured by surface electromyography (semg) and f-scan mobile system during stair climbing. 4. cortical activation is measured by functional near-infrared-spectroscopy (fnirs) (nirscout, nirx, germany) during treadmill gait. in stroke patients, 1. muscle activation and foot pressure distribution are measured by surface electromyography (semg) and f-scan mobile system during five times sit-to-stand test. 2. cortical activation is measured by functional near-infrared-spectroscopy (fnirs) (nirscout, nirx, germany) during treadmill gait.

Eligibility criteria:
inclusion criteria: * elderly adults 1. age: between 65 and 84 years 2. elderly adults who had no neurological or musculoskeletal abnormalities affecting gait 3. ability to walk at least 10m regardless of assist devices * stroke 1. age: between 20 and 84 years 2. ≥ 3 months post stroke 3. ability to walk at least 10m regardless of assist devices 4. adequate gait function (fac \> 3) 5. physician approval for patient participation exclusion criteria: * elderly adults 1. history of any diseases (eg. lower extremity orthopedic diseases, neurologic disorders, cardiovascular disease, heart failure, uncontrolled hypertension that affect walking capacity, efficiency, and endurance) 2. severe visual impairment or dizziness that increases the risk of falls * stroke 1. serious cardiac conditions (hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living) 2. advanced liver, kidney, cardiac, or pulmonary disease 3. history of concussion in last 6 months 4. history of unexplained, recurring headaches, epilepsy/seizures/skull fractures or skull deficits 5. preexisting neurological disorders such as parkinson's disease, amyotrophic lateral sclerosis (als), multiple sclerosis (ms), dementia

Keywords: exoskeleton device elderly stroke
efficacy of calprotectin as a marker for the pathogenicity of blastocystis infection

Conditions: Blastocystis Infections

Summary: blastocystis which is commonly found in the gastro-intestinal tract, has been recognized as a non-pathogenic organism for a few decades. it has a variable distribution. a high prevalence has been reported in developing countries (22.1-100%). in developed countries, the prevalence ranges from 0.5% to 23.1%. the high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food .

blastocystis which is commonly found in the gastro-intestinal tract, has been recognized as a non-pathogenic organism for a few decades. it has a variable distribution. a high prevalence has been reported in developing countries (22.1-100%). in developed countries, the prevalence ranges from 0.5% to 23.1%. the high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food. the pathogenicity of blastocystis is controversial because most patients carrying this parasite are asymptomatic. several studies have considered blastocystis sp. as a commensal micro-organism, while other results have showed the pathogenicity of the parasite. calprotectin (cp), a calcium-binding protein, comprises 60% of cytosolic protein found in neutrophils. fecal calprotectin (f-cp) concentration is an indicator of neutrophil migration into the intestinal lumen and is associated with intestinal inflammation.

Eligibility criteria:
inclusion criteria: * patients from outpatient clinics, sohag hospitals. exclusion criteria: * patients taking antibiotics within the previous four weeks, and anti-parasitic drugs within the previous two weeks.

Keywords: blastocystis calprotectin
percutaneous electrical nerve stimulation and exercise for shoulder pain

Conditions: Shoulder Pain

Summary: based on the available literature, application of percutaneous electrical nerve stimulation interventions targeting peripheral nerves (also called percutaneous neuromodulation) has shown positive effects for improving pain-related and functional outcomes in musculoskeletal chronic pain. studies investigating the use of this intervention for the shoulder are lacking.

based on the available literature, application of percutaneous electrical nerve stimulation interventions targeting peripheral nerves (also called percutaneous neuromodulation) has shown positive effects for improving pain-related and functional outcomes in musculoskeletal chronic pain. studies investigating the use of this intervention for the shoulder are lacking.

Eligibility criteria:
inclusion criteria: * unilateral non-traumatic shoulder pain (positive painful arc during shoulder abduction and a positive hawkins test on clinical examination) * shoulder pain from at least 3 months * shoulder pain of more than 3/10 points on a nprs exclusion criteria: * bilateral shoulder symptoms * younger than 18 or older than 65 years * history of shoulder traumatisms, fractures or dislocation * diagnosis of cervical radiculopathy or myelopathy * previous interventions with steroid injections in the shoulder area * comorbid medical conditions, e.g., fibromyalgia syndrome * previous history of shoulder or neck surgery * any type of intervention for the neck-shoulder area during the previous year * fear to needles

Keywords: neuromodulation percutaneous nerve stimulation exercise
safe options for acl recovery

Conditions: Anterior Cruciate Ligament Injuries; Opioid Use

Summary: the purpose of the proposed work is to test a brief opioid exposure reduction program (acl-oerp) designed to improve health literacy about opioid use following surgeries. this intervention is specifically designed to be used with patients (or for patients under 18, the patient and caregiver) undergoing anterior cruciate ligament (acl) reconstruction, a painful surgery that is often followed by at least 7 days of opioid medication.

the goal of this study is to test whether the acl-oerp intervention (vs. a treatment as usual \[tau\] comparison) improves knowledge of (1) risks associated with opioid self-administration (development of tolerance, dangers of concomitant sedative use, taking as prescribed for safety), (2) expected pain following acl reconstruction, (3) accurate pain assessment, (4) and weaning from opioid to non-narcotic analgesics. there will be one control arm (tau) and two intervention arms, both of which are experimental. both will receive the acl-oerp before surgery, and the second arm will also receive a "booster" intervention session of the intervention 3 days after surgery. in addition, investigators wish to compare the amount of opioid self-administered in the intervention groups (vs. tau comparison) to assess whether this knowledge reduces self-administration of opioid. the project will also examine whether the implementation of the booster intervention session in the third arm improves these outcomes compared to the other intervention arm.

Eligibility criteria:
inclusion criteria: * presenting for a pre-operatory appointment at the study site for acl reconstruction with patellar tendon autograft surgery. * be able to return to the clinic at least one time within the first 10 days post-op. exclusion criteria: * under 12 years of age * contraindication to opioids * unable to understand intervention material in english

Keywords: prevention opioid exposure exposure reduction